DYRONIB 50mg Tablet contains the active substance Dasatinib. It belongs to a group of medicines known as Tyrosine Kinase Inhibitors (TKIs). It is primarily indicated for the treatment of Philadelphia chromosome-positive Chronic Myeloid Leukemia (Ph+ CML) and Philadelphia chromosome-positive Acute Lymphoblastic Leukemia (Ph+ ALL). Dasatinib helps control the growth of abnormal blood cells and is often prescribed when other leukemia treatments are ineffective or not tolerated.
Dasatinib works by blocking abnormal proteins that signal cancer cells to grow and multiply. This helps slow disease progression and supports the restoration of normal blood cell production.
DYRONIB 50mg Tablets should be used under the strict supervision of an oncologist or hematologist, with regular blood count monitoring throughout treatment.
Uses of DYRONIB 50mg Tablets
- Treatment of Philadelphia chromosome-positive Chronic Myeloid Leukemia (Ph+ CML)
- Treatment of Philadelphia chromosome-positive Acute Lymphoblastic Leukemia (Ph+ ALL)
- Management of leukemia resistant to previous therapies
- Long-term control of blood cancer progression
- Targeted cancer therapy for specific genetic mutations
Therapeutic Effects of DYRONIB 50mg Tablets
DYRONIB 50mg Tablets exert their therapeutic effect by inhibiting BCR-ABL tyrosine kinase, an abnormal protein produced by the Philadelphia chromosome. By blocking this protein, Dasatinib prevents cancer cell growth and division, helping reduce the number of abnormal blood cells and improve treatment outcomes.
Interaction of DYRONIB 50mg Tablets with Other Drugs
It is important to inform your healthcare professional about all medicines you are taking, including prescription medications, supplements, and herbal products.
Notable interactions include:
-
Amiodarone: Increased risk of serious heart rhythm problems.
-
Domperidone: May increase cardiac side effects.
-
Hydroxyzine: Increased risk of QT prolongation.
-
Antacids containing aluminum, calcium, or magnesium: May reduce Dasatinib absorption.
-
Other chemotherapy medicines: Increased risk of toxicity and bone marrow suppression.
More Information about DYRONIB 50mg Tablets
- Keep out of reach of children and pets.
- Store below 30°C.
- Protect from moisture and direct sunlight.
- Keep in original packaging.
- Do not use after the expiry date.
How to Consume DYRONIB 50mg Tablets
DYRONIB 50mg Tablets are oral medications meant to be swallowed whole with a glass of water. They may be taken with or without food.
Do not crush, chew, or break the tablets. Take the medicine exactly as prescribed by your doctor and preferably at the same time each day. Avoid grapefruit juice during treatment as it may affect the medicine's effectiveness.
Safety Advice for DYRONIB 50mg Tablets
Breast Feeding
Unsafe / Contraindicated
Dasatinib may pass into breast milk and can harm the infant. Breastfeeding should be avoided during treatment.
Alcohol
Consult Your Doctor
The safety of alcohol consumption during Dasatinib therapy is not clearly established. Consult your healthcare provider.
Liver
Caution
Patients with severe liver disease may require dose adjustments and close monitoring.
Kidneys
Generally Safe Under Medical Supervision
Dose adjustment is usually not required in most patients with kidney impairment, but monitoring may be necessary.
Driving
Caution
DYRONIB may cause dizziness, drowsiness, or blurred vision. Avoid driving if affected.
Pregnancy
Unsafe / Contraindicated
Dasatinib can cause serious fetal harm and should not be used during pregnancy. Effective contraception is recommended during treatment.
Side Effects of DYRONIB 50mg Tablets
Side effects are unwanted symptoms caused by medicines. Although not everyone experiences them, some patients may develop side effects.
Common Side Effects of DYRONIB 50mg Tablets
- Headache
- Nausea and vomiting
- Diarrhea
- Fatigue
- Rash
- Muscle pain
- Joint pain
- Anemia
Serious Side Effects of DYRONIB 50mg Tablets
- Pleural effusion (fluid around the lungs)
- Pulmonary hypertension
- Severe bleeding
- Heart failure
- Severe infections
- Bone marrow suppression
- Low platelet and white blood cell counts
Word of Advice
Regular blood tests, liver function monitoring, and clinical assessments are essential during treatment with DYRONIB 50mg Tablets. Contact your doctor immediately if you experience breathing difficulties, chest pain, unusual bleeding, persistent fever, or severe fatigue. Avoid self-medication and inform your healthcare provider about all medicines you are taking.
FAQs about DYRONIB 50mg Tablets
Q1. What is DYRONIB 50mg Tablet used for?
It is used to treat Philadelphia chromosome-positive Chronic Myeloid Leukemia (Ph+ CML) and Acute Lymphoblastic Leukemia (Ph+ ALL).
Q2. How does DYRONIB work?
It blocks abnormal tyrosine kinase proteins that drive cancer cell growth and multiplication.
Q3. Can DYRONIB cause lung-related complications?
Yes. One serious side effect is pleural effusion, which involves fluid buildup around the lungs and may cause breathing difficulties.
Q4. What should I do if I miss a dose?
Take the missed dose as soon as you remember. If it is nearly time for the next dose, skip the missed dose and continue with your normal schedule. Do not double the dose.
Q5. Can DYRONIB increase the risk of infections?
Yes. The medicine may lower white blood cell counts, increasing susceptibility to infections. Seek medical attention if you develop fever or signs of infection.
Fact Box of DYRONIB 50mg Tablets
Molecule Name: Dasatinib 50mg
Therapeutic Class: Antineoplastic Agents
Pharmacological Class: Tyrosine Kinase Inhibitors (TKIs)
Indications: Philadelphia Chromosome-Positive Chronic Myeloid Leukemia (Ph+ CML), Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL), Resistant or Intolerant Leukemia Cases.
